Q&A: Joe Jimenez talks about salvaging ‘stuck’ drugs and why a substance abuse treatment could be worth billions of dollars

For four years, former Novartis CEO Joe Jimenez and his research righthand, Mark Fishman, have been running Aditum Bio. The Oakland, CA-based venture firm in-licenses drugs on the cusp of human trials and puts them into individual companies that can be sold off if the early-stage results are good.

Click here to view original post